相关临床试验
11
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
18.2%
尚未招募
4
36.4%
招募中
3
27.3%
终止
1
9.1%
撤回
1
9.1%
暂无批准数据
- World Radiotherapy Awareness Day (WRAD), celebrated September 7, promotes the theme "One Voice for Radiotherapy" to ensure every patient has access to safe, effective radiotherapy. - Over half of people with cancer require radiotherapy, yet an estimated one in five eligible Australian patients does not receive it in line with best practice care. - Global radiotherapy demand is projected to rise from 10 million patients in 2022 to 21 million by 2050, requiring substantial workforce expansion. - An additional 84,000 radiation oncologists, 47,000 medical physicists, and 141,000 radiation therapists are needed to meet projected demand.
- Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies. - Both patients in the first cohort completed 4-hour treatments without device deficiencies or immediate complications, with safety data to be reviewed by an independent Data Safety Monitoring Board. - The approximately 18-patient trial aims to evaluate whether removing tumor-derived extracellular vesicles can improve response rates to pembrolizumab or nivolumab, which currently show lasting responses in only 30-40% of patients. - The Hemopurifier holds FDA Breakthrough Device designation and is designed to bind and remove extracellular vesicles implicated in cancer metastasis and immunotherapy resistance.
- Radiopharm Theranostics has expanded its strategic research collaboration with GenesisCare to conduct Phase I trials of three radiopharmaceutical candidates targeting hard-to-treat cancers in Australia. - The trials will evaluate a PDL-1 targeting nano-mAb for non-small cell lung cancer, a PTPu targeting peptide for brain tumors, and a PSA targeting antibody for prostate cancer. - Radiopharmaceuticals deliver small doses of radiation to specifically targeted cells for therapeutic or diagnostic purposes, offering new hope to patients who have exhausted other treatment options. - The two-year collaboration leverages GenesisCare's contract research organization capabilities across its 440+ locations in Australia, UK, US, and Spain.
- Clarity Pharmaceuticals has opened enrollment for the phase 1/2 COBRA trial evaluating 64Cu SAR-bisPSMA in 50 patients with biochemically recurrent prostate cancer following definitive therapy. - The novel PSMA-PET imaging agent aims to improve detection of prostate cancer recurrence, particularly low-volume disease, with enhanced accessibility through central manufacturing and on-demand delivery. - Multiple ongoing trials are exploring 64Cu SAR-bisPSMA applications, including the X-Calibur trial recruiting 150 patients and the SECURE trial combining imaging with targeted therapy in metastatic disease. - Preliminary data from Clarity's earlier trials indicate high uptake of the copper-64 agent, suggesting potential for improved diagnostic accuracy in biochemical recurrence patients.
